The mission of the Alzheimer’s Association Business Consortia (AABC) is to advance Alzheimer’s disease (AD) research and innovation in small, start-up biotechnology, diagnostic and contract research organizations.

The AABC works to achieve its mission by working on areas of common interest in a pre-competitive space to advance both the field of Alzheimer’s research and the member companies' goals. The AABC member companies provide leadership and direction to the organization’s areas of focus that include but are not limited to:

Collaborations

Collaborations are very valuable to small companies as a way to share resources, expand infrastructure, save money and potentially create income. The consortia will provide a platform for companies looking for collaboration opportunities within the consortia between member companies. The Alzheimer’s Association will provide a space on its web-site for the consortia companies to share information and develop relationships. The consortia members will also share ideas on how to develop collaborations with large companies external to the consortia.

Recognition and visibility

Small companies will benefit from publications and positive publicity. As such, the AABC will look for ways to bring companies in this sector to the attention of the AD R&D community through publications and posters. As an example, the AABC may present a poster at an upcoming AAIC.

Knowledge and information sharing

The AABC will look for ways to share knowledge and information in a pre-competitive space. The group will share information about each member company. They may also share information on trusted consultants, CRO’s, ways to manage data in a small company, funding strategies and funding sources.

AABC / ISTAART Webinars

May 2017
Araclon ISTAART
Cytox Intro
DiamiR ISTAART
NanoSomiX ISTAART

May 2018
National Institute on Aging Small Business Award Program

Company summaries

3R
712 North
Accera
Acelot
ADMdx
AdVax
Altoida
Amylyx Pharmaceuticals
Asceneuron
Aulesa
BioPegasus LLC
CSP Telemedicine
DC Limited
InterVivo
M3 Biotechnology, Inc.
NanoSomiX
NeuraMetrix
NeuroScios
nPharmakon
Presympto
Proclara
QMENTA 
Really
Septa Therapeutics
Siragen
SynAging
Telocyte
Treventis

Agenda/Meeting Minutes

July 23, 2018 Agenda (PDF)
Meeting minutes (PDF)
February 15, 2018 Agenda (PDF)
Meeting minutes (PDF)
November 1, 2017 Agenda (PDF)
Meeting minutes (PDF)
February 1, 2017 Agenda (PDF)
Meeting minutes (PDF)
December 9, 2016 Meeting minutes (PDF)
October 19, 2015 Agenda (PDF)
Meeting minutes (PDF)
August 25, 2015 Agenda (PDF)
Meeting minutes (PDF)
July 21, 2015 Agenda (PDF)
Meeting minutes (PDF)
Questionnaire results (PDF)
May 13, 2015 Agenda (PDF)
Meeting minutes (PDF)
March 2, 2015 Agenda (PDF)
Meeting minutes (PDF)
November 18, 2014 Agenda (PDF)
Meeting minutes (PDF)

Publications

Maximizing the Potential of Small Companies in Alzheimer’s Disease Research: Challenges and Opportunities (PPT)
Maximizing the Potential of Small Companies in Alzheimer’s Disease Research: Challenges and Opportunities (PPT)

Newsletter

Quarter 1 and 2 2018 newsletter
Quarter 3 2017 newsletter
Quarter 2 2017 newsletter
Quarter 4 2017 newsletter
Quarter 3 2016 newsletter
Quarter 2 2016 newsletter
Quarter 4 2015 newsletter

Webinars

NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease - November 2018 (PPT)
Ask the Expert - August 2018 (PPT)
IR and PR Strategy for Emerging Alzheimer's Companies - June 2018 (PDF)
Ask The Expert - December 2017 (PDF)
AABC/ISTAART Joint Webinar - October 19, 2017 (PDF)
Ask The Expert - September 2017 (PPT)
Ask The Expert - June 2017 (PPT)
Ask The Expert - April 2017 (PPT)
SBIR/STTR funding for Alzheimer's disease (PDF)
What does pharma look for in evaluating companies as potential partners? (PDF)
Speaker: Declan Jones, Vice President, Neuroscience Lead, J&J Innovation Center; Wednesday, February 24, 2016 11:00 A.M. ET / 8:00 A.M. PT

Translational Animal Models

For the purposes of the AABC Working Group, the following description of Alzheimer's disease translational models is proposed.

Translational animal models of Alzheimer's disease should parallel both the development of progressive clinical pathology in humans with Alzheimer's disease as well as the symptomatology including deficits across multiple cognitive domains and in activities of daily living. Interventions that change the course of pathology or cognitive/symptomatic outcomes in the animal models will be validated if they also change the course of pathology in Alzheimer's patients in a similar fashion, or vice versa. To enhance their utility for drug discovery purposes, the pathological features measured over the course of the disease may include fluid-based biomarkers and metabolites, changes in brain/body pathologies measured by MRI or PET, biochemical changes in the brain detected by MRS, post-mortem neuropathological hallmarks of the disease as well as synaptic loss and inflammation, and quantifiable changes in cognitive function measured using multi-cognitive domain specific testing.

The validity of animal models to predict likely effects in human clinical trials is challenging for neurological diseases such as Alzheimer's disease due to species differences across numerous factors. As such, the limitations of each animal model must be recognized. In general, the animal model with the fewest number of limitations will have the greatest potential value to predict human outcomes. A further challenge is to decide which clinical outcomes are the most informative for predicting clinical success of Alzheimer's disease therapeutics. Since Alzheimer's disease develops over time, the clinical outcomes measured may need to be different at different disease stages, or times of disease progression, and animal models demonstrating a greater number of testable modalities that parallel this progressive nature of the disease will have greater value.

Upcoming Event:

Alzheimer’s Association Business Consortium
Translational Animal Models for Alzheimer’s Disease Think Tank
November 28-29, 2018
Park Hyatt Hotel
Washington, D.C.

Guest logistics
Agenda

(Please note: Space is limited, registration is required. Register here.)
 

For more information

For investigators who are interested in more information on the AABC, please contact Rebecca Edelmayer, Ph.D.

Rebecca Edelmayer, Ph.D.
Director, Scientific Engagement
Medical & Scientific Relations
Alzheimer's Association
rmedelmayer@alz.org